Cost comparison analysis of onasemnogene abeparvovec and nusinersen for treatment of patients with spinal muscular atrophy type 1 in the Netherlands. - van der Schans S; Velikanova R; Weidlich D; Howells R; Patel A; Bischof M; Postma MJ; Boersma C (The European journal of health economics : HEPAC : health economics in prevention and care, 2025)